ClinicalTrials.gg
Not yet recruitingNCT07850466Updated Sep 30, 2026

TRPTI Metabolic and GLP-1 Pharmacodynamic Study

A Phase 4 interventional study of TRPTI and Placebo in Overweight , Obesity, sponsored by RDC Clinical Pty Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by RDC Clinical Pty Ltd · Phase 4, Interventional, and Other

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
158th of 169
20 · median 180
Started
2026
with 40 others
Phase 4
8 of 188
1 open now
Primary completion
2027-10
later than 30 of 73 live
Registered
179th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 158th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 8 in phase 4, reaches primary completion later than 30 of the 73 other live ones, and was the 179th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 30 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).

Researchers will compare TRPTI™ 150 mg to a matching placebo capsule to see if TRPTI™ produces a meaningful difference in GLP-1 response and associated metabolic and appetite-related markers over 8 hours.

Participants will attend two 9-hour clinic visits (crossover design, with a minimum 6-day washout between visits).

03

Conditions studied

  • Overweight , Obesity

Browse trials for

Keywords

  • metabolic markers
  • GLP-1
04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 20 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

RDC Clinical Pty Ltd is the lead sponsor of 34 studies on the registry; 8 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 30 years and older
  • Generally healthy
  • 25.0-34.9 kg/m²
  • Able to provide
  • Agree to not participate in another clinical trial while enrolled in this trial
  • Agree not to change current diet and/or exercise frequency or intensity during entire study period
  • Females using a prescribed form of (e.g., oral contraceptive)
  • Participant's ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points
  • Able to attend the clinic on all required days

Exclusion criteria

Exclusion Criteria:

  • Have a serious illness e.g., neurological disorders such as MS, kidney disease, liver disease or heart conditions
  • History of any glucose or insulin regulation problem, including diabetes
  • Have an unstable illness e.g., thyroid gland dysfunction, uncontrolled mood disorders (e.g., depression, anxiety, bipolar)
  • Diagnosed with any known metabolic or endocrine dysfunctions e.g., diabetes, NAFLD, hyperinsulinaemia, hypoglycaemia
  • Use of any medication or supplements that may affect any metabolic pathway associated with satiety (e.g., GLP-1, GIP, glucagon), glucose or insulin
  • Current (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
  • Significant change in diet in the past 1 month (e.g., removal of a food group or calorie restriction)
  • Active smokers, nicotine use or drug (prescription or illegal substances) abuse
  • Chronic past and/or current alcohol use (>21 alcoholic drinks/week)
  • Pregnant or lactating women
  • Allergic to any of the ingredients in active or placebo formula
  • Participants who are or who have participated in any other clinical trial during the past 1 month (excludes RDC clinical trials which are to be assessed on a case-by-case basis)
  • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
  • Regular use within the past 4 weeks of supplements containing OEA and LipiSperse (TRPTITM)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TRPTI

    Participants will receive a single capsule of 150mg TRPTI

    Dietary Supplement: TRPTI

  • Placebo comparator
    Placebo

    Participants will receive a single capsule of placebo

    Other: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Change from baseline in plasma GLP-1 concentration

    Change from baseline in plasma GLP-1 concentration at each individual post-dose time point (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 6, 7, and 8-hours post-dose). Comparing TRPTI 150 mg to placebo

    Time frame: Baseline to 8hrs

Secondary outcomes

  1. GLP-1 area under the curve (AUC)

    GLP-1 area under the curve (AUC) 0: total (0-8 h) and pre-defined blocks (0-15 min, 15 min-2 h, 2-4 h, 4-6 h, 6-8 h). Comparing TRPTI 150 mg to placebo

    Time frame: Baseline to 8hrs

  2. Change from baseline at each individual time point for: GIP

    Change from baseline at each individual time point for: GIP

    Time frame: Baseline to 8hrs

  3. Change from baseline at each individual time point for: DPP-4 (dipeptidyl peptidase-4)

    Change from baseline at each individual time point for: DPP-4 (dipeptidyl peptidase-4)

    Time frame: Baseline to 8hrs

  4. Change from baseline at each individual time point for: glucose

    Change from baseline at each individual time point for: glucose

    Time frame: Baseline to 8hrs

  5. Change from baseline at each individual time point for: insulin

    Change from baseline at each individual time point for: insulin

    Time frame: Baseline to 8hrs

  6. AUC (total and blocks) for: GIP

    AUC (total and blocks) for: GIP

    Time frame: Baseline to 8hrs

  7. AUC (total and blocks) for: DPP-4

    AUC (total and blocks) for: DPP-4

    Time frame: Baseline to 8hrs

  8. AUC (total and blocks) for: glucose

    AUC (total and blocks) for: glucose

    Time frame: Baseline to 8hrs

  9. AUC (total and blocks) for: insulin

    AUC (total and blocks) for: insulin

    Time frame: Baseline to 8hrs

  10. Tmax for GLP-1

    Tmax for GLP-1

    Time frame: Baseline to 8hrs

  11. Tmax for DPP-4

    Tmax for DPP-4

    Time frame: Baseline to 8hrs

  12. Tmax for glucose

    Tmax for glucose

    Time frame: Baseline to 8hrs

  13. Tmax for insulin

    Tmax for insulin

    Time frame: Baseline to 8hrs

  14. Cmax for GLP-1

    Cmax for GLP-1

    Time frame: Baseline to 8hrs

  15. Cmax for DPP-4

    Cmax for DPP-4

    Time frame: Baseline to 8hrs

  16. Cmax for glucose

    Cmax for glucose

    Time frame: Baseline to 8hrs

  17. Cmax for insulin

    Cmax for insulin

    Time frame: Baseline to 8hrs

  18. Tolerability including GIT tolerance

    Tolerability including gastrointestinal (GIT) tolerance will be measured via a Gastronintestinal tolerance questionnaire and GIT adverse events.

    Time frame: Baseline to 8 hours

  19. Safety via AE monitoring

    Safety via AE monitoring

    Time frame: Baseline to 8 hours

Other outcomes

  1. Exploratory: Change from baseline at each individual time point for glucagon

    Exploratory: Change from baseline at each individual time point for glucagon

    Time frame: Baseline to 8 hours

  2. Exploratory: Change from baseline at each individual time point for PYY (peptide YY)

    Exploratory: Change from baseline at each individual time point for PYY (peptide YY)

    Time frame: Baseline to 8 hours

  3. Exploratory: AUC (total and blocks) for glucagon

    AUC (total and blocks) for glucagon

    Time frame: Baseline to 8 hours

  4. Exploratory: AUC (total and blocks) for PYY

    AUC (total and blocks) for PYY

    Time frame: Baseline to 8 hours

  5. Exploratory: Tmax for glucagon

    Tmax for glucagon

    Time frame: Baseline to 8 hours

  6. Exploratory: Tmax for PYY

    Tmax for PYY

    Time frame: Baseline to 8 hours

  7. Exploratory: Cmax for glucagon

    Tmax for glucagon

    Time frame: Baseline to 8 hours

  8. Exploratory: Cmax for PYY

    Tmax for PYY

    Time frame: Baseline to 8 hours

  9. Exploratory: Visual analogue scale (VAS) for appetite

    VAS for appetite

    Time frame: Baseline to 8hrs

  10. Exploratory: Food consumption during time in clinic

    Food consumption during time in clinic

    Time frame: Baseline to 8 hours

  11. Exploratory: E/LFT

    Blood sample taken for E/LFT

    Time frame: Baseline to 8 hours

  12. Exploratory: Subgroup analysis by BMI stratum

    Subgroup analysis by BMI stratum (BMI 25.0-29.9 vs BMI 30.0-34.9).

    Time frame: Baseline

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 210 phase 4 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 30, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07850466
Collaborators
Gencor Pacific Limited, Hong Kong
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

David Briskey
Contact
research@rdcglobal.com.au
+61(0)731024486
RV Venkatesh
study director · Gencor Pacific

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-oleoylethanolamine

Start the discussion